Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Sinopharm unit inches toward vaccine breakthrough

    By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
    Share
    Share - WeChat
    A China National Biotech Group Co Ltd employee displays a COVID-19 inactive vaccine, which is under development and trials, at the company's research institute in Wuhan, capital of Hubei province, on April 10. [Photo/Xinhua]

    State-owned CNBG teams up with partners to step up development of effective, lasting treatment for COVID-19

    Chinese State-owned pharmaceutical giant Sinopharm Group has made substantial progress in developing vaccine candidates for the novel coronavirus that causes COVID-19.

    China National Biotech Group Co Ltd, Sinopharm's vaccine and bioscience unit, announced on Monday that its second inactivated vaccine targeting the contagion won clinical trial approval from the National Medical Products Administration. The vaccine is codeveloped by a unit under CNBG-Beijing Institute of Biological Products Co Ltd-and the Chinese Center for Disease Control and Prevention.

    On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.

    Approved for clinical trials on April 12, the vaccine was the first inactivated vaccine worldwide to reach such a developed approval stage. The NMPA authorized its phase-1 and phase-2 human trials at the same time on that day through a fast-track channel based on solid results from preclinical trial studies.

    "The world is racing to develop COVID-19 vaccines, yet it is not a competition between countries, but rather a race between humans and the virus," said Yang Xiaoming, president of CNBG.

    Yang said it is quite encouraging to have developed inactivated vaccines against COVID-19.

    Inactivated vaccines use nonliving viruses, bacteria or other pathogens that have lost disease-producing capacity to stimulate the immune system to develop an immune response.

    Wang Junzhi, an academic at the Chinese Academy of Engineering, said China has laid a solid foundation to research inactivated vaccines in recent years, and inactivated vaccines have been widely used to fight hepatitis A, influenza, poliomyelitis, and hand, foot and mouth disease.

    Yang added that China has distinctive advantages in developing vaccines against the disease thanks to the country's institutional features that can unite resources and efforts of different participants to concentrate on a specific program and target.

    1 2 3 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    69天堂人成无码麻豆免费视频| 再看日本中文字幕在线观看| 中文精品99久久国产| 大学生无码视频在线观看| 精品无码国产自产在线观看水浒传| 一级电影在线播放无码| 无码国内精品人妻少妇蜜桃视频| 国产精品综合专区中文字幕免费播放| 久久国产三级无码一区二区| 亚洲日韩欧洲无码av夜夜摸| 色综合久久中文综合网| 亚洲一级Av无码毛片久久精品| 无码精品人妻一区二区三区漫画 | 最新中文字幕AV无码不卡| A狠狠久久蜜臀婷色中文网| 免费无码黄十八禁网站在线观看| 无码一区二区三区老色鬼| 中文字幕无码免费久久| 中文字幕av高清有码| 最近中文字幕免费2019| 7国产欧美日韩综合天堂中文久久久久| 婷婷色中文字幕综合在线 | 国产精品无码一区二区在线观一| 亚洲国产综合无码一区| 制服丝袜日韩中文字幕在线| 最近免费2019中文字幕大全| 久久精品中文字幕久久| 亚洲中文久久精品无码| 丝袜熟女国偷自产中文字幕亚洲| 亚洲AV无码一区二区大桥未久| 嫩草影院无码av| 亚洲欧美日韩中文播放| 中文字幕精品无码久久久久久3D日动漫| 国产精品无码免费专区午夜| 精品人妻少妇嫩草AV无码专区 | 中中文字幕亚洲无线码| 亚洲AV无码一区二区三区国产| 无码日韩人妻AV一区免费l| 亚洲人成人无码网www国产| 中文字幕乱码人妻无码久久| 精品久久无码中文字幕|